Literature DB >> 8876139

Negative-strand RNA viruses: genetic engineering and applications.

P Palese1, H Zheng, O G Engelhardt, S Pleschka, A García-Sastre.   

Abstract

The negative-strand RNA viruses are a broad group of animal viruses that comprise several important human pathogens, including influenza, measles, mumps, rabies, respiratory syncytial, Ebola, and hantaviruses. The development of new strategies to genetically manipulate the genomes of negative-strand RNA viruses has provided us with new tools to study the structure-function relationships of the viral components and their contributions to the pathogenicity of these viruses. It is also now possible to envision rational approaches--based on genetic engineering techniques--to design live attenuated vaccines against some of these viral agents. In addition, the use of different negative-strand RNA viruses as vectors to efficiently express foreign polypeptides has also become feasible, and these novel vectors have potential applications in disease prevention as well as in gene therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8876139      PMCID: PMC38061          DOI: 10.1073/pnas.93.21.11354

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.

Authors:  J I Cohen; F Wang; J Mannick; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

2.  Rescue of a foreign gene by Sendai virus.

Authors:  K H Park; T Huang; F F Correia; M Krystal
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

3.  In vitro mutagenesis of a full-length cDNA clone of Semliki Forest virus: the small 6,000-molecular-weight membrane protein modulates virus release.

Authors:  P Liljeström; S Lusa; D Huylebroeck; H Garoff
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  Rescue of synthetic analogs of respiratory syncytial virus genomic RNA and effect of truncations and mutations on the expression of a foreign reporter gene.

Authors:  P L Collins; M A Mink; D S Stec
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

5.  Production of infectious RNA transcripts from Sindbis virus cDNA clones: mapping of lethal mutations, rescue of a temperature-sensitive marker, and in vitro mutagenesis to generate defined mutants.

Authors:  C M Rice; R Levis; J H Strauss; H V Huang
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

6.  Rescue of synthetic analogs of genomic RNA and replicative-intermediate RNA of human parainfluenza virus type 3.

Authors:  K Dimock; P L Collins
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

7.  High-efficiency formation of influenza virus transfectants.

Authors:  M Enami; P Palese
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

8.  Vaccinia virus: a selectable eukaryotic cloning and expression vector.

Authors:  M Mackett; G L Smith; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

9.  Introduction of site-specific mutations into the genome of influenza virus.

Authors:  M Enami; W Luytjes; M Krystal; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

10.  Biologic importance of neuraminidase stalk length in influenza A virus.

Authors:  M R Castrucci; Y Kawaoka
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more
  32 in total

Review 1.  Reverse genetics of negative-strand RNA viruses: closing the circle.

Authors:  A Pekosz; B He; R A Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  "Rule of six": how does the Sendai virus RNA polymerase keep count?

Authors:  D Vulliémoz; L Roux
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge.

Authors:  S Mark Tompkins; Yuan Lin; George P Leser; Kari A Kramer; Debra L Haas; Elizabeth W Howerth; Jie Xu; Mary J Kennett; Russell K Durbin; Joan E Durbin; Ralph Tripp; Robert A Lamb; Biao He
Journal:  Virology       Date:  2007-01-23       Impact factor: 3.616

4.  Reverse genetics system for introduction of site-specific mutations into the double-stranded RNA genome of infectious rotavirus.

Authors:  Satoshi Komoto; Jun Sasaki; Koki Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-14       Impact factor: 11.205

Review 5.  RNA virus vectors: where are we and where do we need to go?

Authors:  P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

6.  A DNA transfection system for generation of influenza A virus from eight plasmids.

Authors:  E Hoffmann; G Neumann; Y Kawaoka; G Hobom; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

7.  Recombinant Newcastle disease virus as a vaccine vector.

Authors:  T Nakaya; J Cros; M S Park; Y Nakaya; H Zheng; A Sagrera; E Villar; A García-Sastre; P Palese
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

8.  Generation of influenza A viruses entirely from cloned cDNAs.

Authors:  G Neumann; T Watanabe; H Ito; S Watanabe; H Goto; P Gao; M Hughes; D R Perez; R Donis; E Hoffmann; G Hobom; Y Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

9.  Involvement of the leader sequence in Sendai virus pathogenesis revealed by recovery of a pathogenic field isolate from cDNA.

Authors:  Yutaka Fujii; Takemasa Sakaguchi; Katsuhiro Kiyotani; Cheng Huang; Noriko Fukuhara; Yoshiko Egi; Tetsuya Yoshida
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV.

Authors:  Zhuhui Huang; Subbiah Elankumaran; Abdul S Yunus; Siba K Samal
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.